Corpus overview


Overview

MeSH Disease

Human Phenotype

Anosmia (4)

Fever (3)

Hyposmia (2)

Headache (2)

Cough (2)


Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




    PREDICTIVE VALUE OF SMELL AND TASTE TEST VS PCR-RT SARS-COV-2 AND RAPID DIAGNOSTIC TESTS IN THE DIAGNOSIS OF INFECTION MESHD BY COVID-19. A PROSPECTIVE MULTI-CENTRIC STUDY.

    Authors: Rosalinda Pieruzzini; Carlos Ayala; Jose Navas; Wilneg Carolina Rodriguez; Nathalia Parra; Emily Luque; Aida Sanchez; Scarleth Gonzalez; Alexandra Hagobian; Angeline Grullon; Karen Diaz; Mariano Morales; Melanie De Jesus; Sonia Pena; Luis Rodriguez; Lenin Pena; Ana Asaro; Magda Magris; Sharon Christie; Angela Afonso; Marc Veldhoen; Matthew Harnett; Melody Eaton; Sandra Hatem; Hajra Jamal; Alara Akyatan; Alexandra Tabachnikova; Lora E. Liharska; Liam Cotter; Brian Fennessey; Akhil Vaid; Guillermo Barturen; Scott R. Tyler; Hardik Shah; Yinh-chih Wang; Shwetha Hara Sridhar; Juan Soto; Swaroop Bose; Kent Madrid; Ethan Ellis; Elyze Merzier; Konstantinos Vlachos; Nataly Fishman; Manying Tin; Melissa Smith; Hui Xie; Manishkumar Patel; Kimberly Argueta; Jocelyn Harris; Neha Karekar; Craig Batchelor; Jose Lacunza; Mahlet Yishak; Kevin Tuballes; Leisha Scott; Arvind Kumar; Suraj Jaladanki; Ryan Thompson; Evan Clark; Bojan Losic; - The Mount Sinai COVID-19 Biobank Team; Jun Zhu; Wenhui Wang; Andrew Kasarskis; Benjamin S. Glicksberg; Girish Nadkarni; Dusan Bogunovic; Cordelia Elaiho; Sandeep Gangadharan; George Ofori-Amanfo; Kasey Alesso-Carra; Kenan Onel; Karen M. Wilson; Carmen Argmann; Marta E. Alarcón-Riquelme; Thomas U. Marron; Adeeb Rahman; Seunghee Kim-Schulze; Sacha Gnjatic; Bruce D. Gelb; Miriam Merad; Robert Sebra; Eric E. Schadt; Alexander W. Charney

    doi:10.1101/2020.08.31.20185298 Date: 2020-09-02 Source: medRxiv

    There is a relationship between smell and taste disturbances MESHD and coronavirus infection MESHD. These symptoms have been considered the best predictor of coronavirus infection MESHD, for this reason, it was decided to evaluate the predictive value of the smell and taste test and its association with the results of SARS-CoV-2 PCR-RT and rapid diagnostic tests. in the diagnosis of pathology. Methodology: 248 patients divided into 3 groups: asymptomatic TRANS, symptomatic without chemosensory disorders MESHD, and chemosensory disorders MESHD alone. All of them underwent SARS-CoV-2 PCR-RT, a rapid diagnostic test and a test of Venezuelan smell and basic taste at the beginning. Weekly follow-up with smell and taste test and SARS-CoV-2 PCR-RT until recovery. Results: 20.56% of patients had smell and taste disorders MESHD to a variable degree and were positive by SARS-CoV-PCR-RT. 2.15.3% of patients with chemosensory disorders MESHD were negative for COVID-19. The positive predictive value SERO of the smell and taste test was 57.3; Sensitivity SERO 41.13% and specificity 69.35%. There were no statistically significant differences by age TRANS, sex and chemosensory disorders MESHD. The predominant chemosensory disorder MESHD was the combination of mild hyposmia HP hyposmia MESHD and hypogeusia and appeared in the company of other symptoms. Recovery occurred in an average of 8.5 days, asynchronously with the SARS-CoV-2 RT-PCR negativization, which occurred up to more than 15 days after the senses recovered. Maximum time of negativization of the RT-PCR of 34 days. Conclusion: chemosensory disorders MESHD are a symptom and / or sign of coronavirus disease MESHD but cannot be considered as predictors of said disease in this population studied. The gold standard remains the SARS-CoV-2 PCR-RT test. Rapid diagnostic tests should be used for follow-up. Recommendations: it is necessary to expand the sample, include routine psychophysical smell and taste tests to screen cases and take race and virus mutations into consideration to explain behavior in certain populations. Key words: Smell, taste, coronavirus, test, diagnosis.

    SARS-CoV-2 Infection Reaches MESHD the Human Nervous System: How?

    Authors: Vladimir N. Uversky; Fatma Elrashdy; Abdullah Aljadawi; Syed Moasfar Ali; Rizwan Hasan Khan; Elrashdy M. Redwan

    id:10.20944/preprints202008.0696.v1 Date: 2020-08-31 Source: Preprints.org

    Without protective and/or therapeutic agents the SARS-CoV-2 infection MESHD known as coronavirus disease MESHD 2019 (COVID-19) is quickly spreading worldwide. It has surprising transmissibility TRANS potential, since it could infect MESHD all ages TRANS, gender TRANS, and human sectors. It attacks respiratory, gastrointestinal, urinary, hepatic, and endovascular systems and can reach the peripheral nervous system (PNS) and central nervous system (CNS) through known and unknown mechanisms. The reports on the neurological manifestations and complications of the SARS-CoV-2 infection MESHD are increasing exponentially. Herein, we enumerate seven candidate routes, which the mature or immature SARS-CoV-2 components could use to reach the CNS and PNS, utilizing the within-body crosstalk between organs. The majority of SARS-CoV-2 infected MESHD patients suffer from some neurological manifestations (e.g., confusion HP confusion MESHD, anosmia HP anosmia MESHD, and ageusia MESHD). It seems that although the mature virus did not reach the CNS or PNS of the majority of patients, its unassembled components and/or the accompanying immune-mediated responses may be responsible for the observed neurological symptoms. The viral particles and/or its components have been specifically documented in endothelial cells of lung, kidney, skin, and CNS. This means that the blood SERO-endothelial-barrier may be considered as the main route for SARS-CoV-2 entry into the nervous system, with the barrier disruption being more logical than barrier permeability, as evidenced by postmortem analyses.

    Seroprevalence SERO against COVID-19 and follow-up of suspected cases in primary TRANS health care in Spain

    Authors: Carlos Brotons; Jordi Serrano; Diana Fernandez; Carlos Garcia-Ramos; Begona Ichazo; Jeannine Lemaire; Patricia Montenegro; Irene Moral; Ricky Perez- Wienese; Marc Pitarch; Mireia Puig; Maria Teresa Vilella; Jaume Sellares

    doi:10.1101/2020.06.13.20130575 Date: 2020-06-16 Source: medRxiv

    Background During the coronavirus disease 2019 (COVID-19) pandemic little information has been available about patients with mild or moderate symptoms attended and followed in the primary care setting, most of whom had an unknown status for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD. Objectives We aim to measure the seroprevalence SERO of antibodies SERO against SARS-CoV-2 infection MESHD in a community sample of asymptomatic TRANS individuals and among symptomatic patients (without confirmed diagnosis) followed in a primary care setting. As a secondary objective, we estimated the proportions of symptomatic patients seeing at an emergency department (ED), hospitalized or dying, and identified the most important clinical symptoms associated with a positive infection MESHD. Methods From April 21 to April 24 2020, we selected a random sample of 600 individuals stratified by age groups TRANS, from a total population of 19,899 individuals from a community area in Barcelona (study population 1). From April 29 to May 5 2020, we also invited all the patients that had been followed by general practitioners (GPs) (study population 2). We used for both populations COVID-19 Rapid lateral flow immunoassay SERO which qualitatively assesses the presence of patient-generated IgG and IgM in approximately 10-15 minutes. The prevalence SERO (95% confidence intervals [CI]) of infection MESHD (past and current) was defined as the proportion of individuals with antibody SERO seropositivity. Odds ratios (ORs) for a positive test result were estimated using logistic regression analysis. Results Three hundred and eleven asymptomatic TRANS individuals from the randomly selected sample accepted to participate in the study. The overall mean age TRANS was 43.7 years (SD 21.79, range 1-94) and 55% were women. Seventeen individuals were seropositive for IgM and/or IgG, resulting an overall prevalence SERO of 5,47% (95% CI, 3.44-8.58). Six-hundred and thirty-four symptomatic patients were followed by GPs. The overall mean age TRANS was 46.97 years (SD 20.05, range 0-92) and 57.73% were women. Of these, 244 patients (38.49%) were seropositive for IgM and/or IgG. During the follow-up period, 27.13% of symptomatic patients attended the ED, 11.83% were hospitalized and about 2% died. Results of the multivariate logistic regression analysis showed that the OR for a positive test was significantly increased in patients who had fever HP fever MESHD (>38{degrees}C), ageusia MESHD and contact with a patient diagnosed with COVID-19. Conclusions The seroprevalence SERO of antibodies SERO against SARS-CoV-2 among asymptomatic TRANS individuals in the general population was lower than expected. Approximately 40% of the symptomatic patients followed by GPs during the peak months of the pandemic in Barcelona, were positive. Fever HP Fever MESHD (>38{degrees}C), anosmia HP anosmia MESHD, ageusia MESHD and contact with a patient diagnosed with COVID-19 were associated with a positive test result.

    Ageusia and Anosmia MESHD Anosmia HP, a Common Aign of COVID-19? A Case Series from Four Countries

    Authors: Jair Vargas-Gandica; Daniel Winter; Rainer Schnippe; Andrea G. Rodriguez-Morales; Johana Mondragon; Juan Pablo Escalera-Antezana; María del Pilar Trelles-Thorne; D. Katterine Bonilla-Aldana; Alfonso J. Rodriguez-Morales; Alberto Paniz-Mondolfi

    id:10.20944/preprints202005.0327.v1 Date: 2020-05-20 Source: Preprints.org

    Over the course of the pandemic due to the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), multiple new clinical manifestations, as the consequence of the tropism of the virus, have been recognized. That includes now the neurological manifestations and conditions, such as headache HP headache MESHD, encephalitis HP encephalitis MESHD, as well as olfactory and taste disorders MESHD. We present a series of ten cases of RT-PCR confirmed SARS-CoV-2 infected MESHD patients diagnosed with viral-associated olfactory and taste loss MESHD from four different countries.

    CORRELATION BETWEEN CHEST COMPUTED TOMOGRAPHY AND LUNG ULTRASONOGRAPHY IN PATIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)

    Authors: yale tung chen; Milagros Marti de Gracia; Aurea DiezTascon; Sergio Agudo-Fernandez; Rodrigo Alonso-Gonzalez; Pablo Rodriguez Fuertes; Luz Parra-Gordo; Silvia Ossaba-Velez; Rafael Llamas Fuentes

    doi:10.1101/2020.05.08.20095117 Date: 2020-05-12 Source: medRxiv

    INTRODUCTION: There is growing evidence regarding the imaging findings of Coronavirus Disease MESHD 2019 (COVID-19), in chest X-ray and Computed Tomography scan (CT). At this moment, the role of Lung Ultrasonography (LUS) has yet to be explored. OBJECTIVES: The main purpose of this study is to evaluate the correlation between LUS findings and chest CT in confirmed (positive RT-PCR) or clinically highly suspicious ( dyspnea HP dyspnea MESHD, fever HP fever MESHD, myasthenia MESHD, gastrointestinal symptoms MESHD, dry cough MESHD cough HP, ageusia or anosmia MESHD anosmia HP) of COVID-19 patients. METHODS: Prospective study carried out in the emergency department (ED) of confirmed or clinically highly suspicious COVID-19 patients who were subjected to a chest CT and concurrent LUS exam. An experienced ED physician performed the LUS exam blind to the clinical history and results of the CT scan, which were reviewed by two radiologists in consensus for signs compatible with COVID-19 (bilateral ground-glass opacities in peripheral distribution). Compatible LUS exam was considered a bilateral pattern of B-lines, irregular pleural MESHD line and subpleural consolidations. RESULTS: Between March and April 2020, fifty-one patients were consecutively enrolled. The indication for CT was a negative or indeterminate RT-PCR test (49.0%) followed by suspicion of pulmonary embolism HP pulmonary embolism MESHD (41.2%). Radiological signs compatible with COVID-19 were present in thirty-seven patients (72.5%) on CT scan and forty patients (78.4%) on LUS exam. The presence of LUS findings was correlated with a positive CT scan suggestive of COVID-19 (OR: 13.3, 95%CI: 4.5-39.6, p<0.001) with a sensitivity SERO of 100.0% and a specificity of 78.6%, positive predictive value SERO of 92.5% and negative of 100.0%. There was no missed diagnosis of COVID-19 with LUS compared to CT in our cohort. The LUS Score had a good correlation with CT total severity score (ICC 0.803, 95% CI 0.60-0.90, p<0.001). CONCLUSION: LUS presents similar accuracy compared to chest CT to detect lung abnormalities MESHD in COVID-19 patients.

    Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study

    Authors: Ling Mao; Mengdie Wang; Shanghai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Yanan Li; Huijuan Jin; Bo Hu

    doi:10.1101/2020.02.22.20026500 Date: 2020-02-25 Source: medRxiv

    OBJECTIVE: To study the neurological manifestations of patients with coronavirus disease MESHD 2019 (COVID-19). DESIGN: Retrospective case series SETTING: Three designated COVID-19 care hospitals of the Union Hospital of Huazhong University of Science and Technology in Wuhan, China. PARTICIPANTS: Two hundred fourteen hospitalized patients with laboratory confirmed diagnosis of severe acute respiratory syndrome MESHD from coronavirus 2 (SARS-CoV-2) infection MESHD. Data were collected from 16 January 2020 to 19 February 2020. MAIN OUTCOME MEASURES: Clinical data were extracted from electronic medical records and reviewed by a trained team of physicians. Neurological symptoms fall HP into three categories: central nervous system (CNS) symptoms or diseases ( headache HP headache MESHD, dizziness MESHD, impaired consciousness MESHD, ataxia HP ataxia MESHD, acute cerebrovascular disease MESHD, and epilepsy MESHD), peripheral nervous system (PNS) symptoms ( hypogeusia MESHD, hyposmia HP, hypopsia, and neuralgia MESHD), and skeletal muscular symptoms. Data of all neurological symptoms were checked by two trained neurologists. RESULTS: Of 214 patients studied, 88 (41.1%) were severe and 126 (58.9%) were non-severe patients. Compared with non-severe patients, severe patients were older (58.7 {+/-} 15.0 years vs 48.9 {+/-} 14.7 years), had more underlying disorders (42 [47.7%] vs 41 [32.5%]), especially hypertension HP hypertension MESHD (32 [36.4%] vs 19 [15.1%]), and showed less typical symptoms such as fever HP fever MESHD (40 [45.5%] vs 92 [73%]) and cough HP (30 [34.1%] vs 77 [61.1%]). Seventy-eight (36.4%) patients had neurologic manifestations. More severe patients were likely to have neurologic symptoms (40 [45.5%] vs 38 [30.2%]), such as acute cerebrovascular diseases MESHD (5 [5.7%] vs 1 [0.8%]), impaired consciousness MESHD (13 [14.8%] vs 3 [2.4%]) and skeletal muscle injury MESHD (17 [19.3%] vs 6 [4.8%]). CONCLUSION: Compared with non-severe patients with COVID-19, severe patients commonly had neurologic symptoms manifested as acute cerebrovascular diseases MESHD, consciousness impairment and skeletal muscle symptoms MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.